Answers are grounded in this paper and cite their sources.
Practice review reveals esthetic screening features for EGFR inhibitor-associated eruptions, highlighting conservative barrier protection and timely medical referral.
This practice review examines how estheticians can recognize that papules and pustules developing during epidermal growth factor receptor (EGFR)-targeted cancer therapy may represent a treatment-associated papulopustular eruption rather than acne vulgaris or papulopustular rosacea. It compares observable patterns including treatment timing, lesion morphology, distribution, sensory symptoms, comedones, erythema, flushing, telangiectasia, xerosis, and warning signs. The article explains how the Kosichenko Oncology Barrier Index (K-OBI) converts diagnostic uncertainty into a conservative, non-medical esthetic decision pathway focused on documentation, service modification, Safety Hold, barrier protection, and timely referral. K-OBI is a provisional esthetic decision-support framework and is not a diagnostic or predictive medical instrument.
No takes yet. Share an insight, caveat, or question.
Anna Kosichenko (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: